The development and demise of the corpus luteum (CL) are accompanied by angiogenic and angioregressive processes; however, the mediators of these processes have not been fully identified and characterized. Transcriptional profiling studies revealed the upregulation of cysteine-rich 61 (CYR61) in the CL, about which nothing was previously known. In the present study, we found that over a 12-h period following a single injection of prostaglandin F 2alpha (PGF 2alpha ), RT-PCR revealed the upregulation of CYR61 at 0.5 and 1 h, after which it declined. We also determined that luteal-derived endothelial cells as well as luteal steroidogenic cells are sources of CYR61. Treatment with PGF 2alpha in vitro had no effect on CYR61 expression in luteal-derived endothelial cells, but it increased CYR61 expression in luteal steroidogenic cells. During the estrous cycle, CYR61/CYR61 (transcript/protein) was increased in the Day 4 but not in the Day 10 and Day 16 CL, suggesting that it may be associated with the switch to the angiogenic phenotype. In addition, the specific but transient upregulation of CYR61 by PGF 2alpha in vivo, and in luteal steroidogenic cells but not endothelial cells in vitro, may be part of the mechanism underlying the previously reported transient increase in blood flow during the early onset of luteolysis. This is supported by our preliminary finding that CYR61 transiently inhibited endothelial cell expression of endothelin-converting enzyme 1 mRNA but not endothelin 1. Collectively, the increased expression of CYR61 in the Day 4 CL and its transient increase by PGF 2alpha in Day 6, Day 10, and Day 16 CL indicate that CYR61 may play a role in regulating angiogenesis over the life span of the CL.
INTRODUCTION
Although it is a hallmark of a variety of human pathologies, angiogenesis rarely occurs under normal circumstances. One exception to this rule is found in the female reproductive system. We and others [1] [2] [3] previously suggested that the corpus luteum (CL), an ephemeral gland of the ovary, might be a useful model for studying the mechanisms underlying angiogenesis induction and regression of angiogenesis during the reproductive cycle. Breakdown of the basement membrane that previously separated follicular granulosa and theca cells commences following the ovulatory gonadotropin surge [4, 5] . In addition, endothelial cells from the theca interna proliferate and migrate across the disrupted basement membrane to form new capillary vessels in the granulosa layer [4, 6, 7] . As a result, the latter undergoes a striking transition from an avascular to a vascular compartment, as shown in the rat [5] and in the rabbit [8] , much like the ''switch'' to the angiogenic phenotype that occurs during tumor progression [9, 10] . This angiogenic switch provides the blood supply for the differentiated steroidogenic cells of rabbit and rat CL [8, 11] . and it initiates luteal formation and development during the early stages of the estrous cycle in the cow [1] . At midcycle, ongoing angiogenesis or angiomaintenance is necessary to sustain the increased steroidogenesis by the CL [12, 13] , one of the most vascularized tissues in the body, as shown in the cow [14] . At the end of the estrous cycle, inhibition of angiogenesis along with the regression of preexisting blood vessels accompany the functional and structural demise of the CL [15, 16] . Thus, the development, function, and demise of the CL are intimately linked to angiogenesis, angiomaintenance, and angioregression [17, 18] .
We and others [3, 13, 19, 20] have utilized the CL model to identify and study expression patterns of molecular determinants such as matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMPs) associated with angiogenesis in the mammalian CL. Angiogenesis is a dynamic and complex biological process that is orchestrated by a variety of angiogenic factors. In addition to the MMPs and their endogenous inhibitors, vascular endothelial growth factor (VEGF) [21] [22] [23] [24] , basic fibroblast growth factor (bFGF; official symbol FGF2) in the human [22] and cow [25] , endocrine gland-VEGF (EG-VEGF; official symbol PROK1) in the human [26] , and angiopoietins (ANGPT1 [Ang-1] and ANGPT2 [Ang-2]) [27] have been studied in the CL. These angiogenic factors show distinct expression patterns during the life span of the CL in the human [26] , bovine [28] , and rat [27] . This suggests that different angiogenic factors have a variety of functions during luteal angiogenesis, angiomaintenance, and angioregression.
In a nonfertile cycle, angiogenesis is most intense during the early development of the CL and declines thereafter. When the cycle ends, much less is known about the mechanisms/ processes associated with angioregression during luteolysis [18] . As part of our ongoing initiative to profile the molecular determinants that switch angiogenesis on and off in the bovine CL, we performed transcriptional profiling studies on CL collected 0.5 h following injection of prostaglandin F 2a (PGF 2a ), the natural luteolysin in ruminants. We identified and confirmed the differential expression of cysteine-rich 61 (CYR61), an angiogenic inducer. CYR61 is a member of the connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family of proteins, which consists of extracellular matrix (ECM)-associated signaling proteins including CYR61, connective tissue growth factor (CTGF), nephroblastoma overexpressed gene, and WNT1-induced secreted proteins (WISPs 1, 2, and 3) [29] . CYR61 is a secreted, ECM-associated, heparin-binding protein that promotes endothelial cell adhesion, migration, and growth factor (FGF2)-induced DNA synthesis [30] . Whereas CTGF has been described in the pig follicle and CL [31] , to our knowledge no reports of CYR61 in the CL have appeared. In the present study, we investigated the temporal regulation of CYR61 by PGF 2a in vivo and in vitro. Furthermore, we determined the pattern of CYR61 expression over the estrous cycle and its cellular localization in bovine CL.
MATERIALS AND METHODS

Overview of Experimental Design
Corpora lutea were collected from cows on Days 6, 10, and 16 of the estrous cycle 0.5 h after PGF 2a or saline injection. Transcriptional profiling was performed on pooled Day 6 CL from PGF 2a -and saline-treated cows. The upregulation of the CYR61 gene was confirmed by semiquantitative RT-PCR analysis of each CL collected as described above. Temporal expression of the CYR61 gene was further defined by injecting Day 10 cows with PGF 2a and collecting CL at 0.5, 1, 2, 4, 8, and 12 h after treatment for analysis by RT-PCR. Furthermore, luteal tissue from Day 10 CL was processed for immunofluorescence and dissociated to investigate expression of and regulation by CYR61 in vitro. For the in vitro experiments, luteal steroidogenic cells (LSCs) and luteal-derived endothelial cells (LDECs) were treated with PGF 2a , and expression of the CYR61 transcript over 24 h was determined by RT-PCR. In addition, LDECs were treated with recombinant CYR61 to study its effects on the endothelin system. Lastly, CL at Days 4, 10, and 16 of the estrous cycle were collected and analyzed for CYR61 gene and protein expression. Animal treatments and tissue collection for transcriptional profiling, CYR61 expression over the estrous cycle, LSC cultures, and immunofluorescence were conducted at the University of New Hampshire, whereas animal treatments and tissue collection for the temporal expression of CYR61 after PGF 2a injection were conducted at the Ohio State University. All sample analyses, LDEC cultures, and expression and purification of recombinant CYR61 were conducted at Children's Hospital Boston.
Animals and Tissue Collection
All animal procedures in the present study were performed according to protocols approved by the Institutional Animal Care and Use Committees at the University of New Hampshire and the Ohio State University. CL were collected from cyclic, nonlactating dairy cows housed at the University of New Hampshire's Fairchild Dairy Teaching and Research Center and at the Krauss Dairy Center at the Ohio Agricultural Research and Development Center using previously reported procedures [32, 33] . To profile gene expression during the early onset of luteal regression, PGF 2a (25 mg) or saline (control) was injected intramuscularly into cows on Day 6, 10, or 16 of the estrous cycle (Day 0 ¼ estrus; n ¼ 3 for each stage). CL were collected 0.5 h after PGF 2a or saline injection and stored at À808C until later analysis.
To determine CYR61 expression over the estrous cycle, Day 4 (early stage; n ¼ 3), Day 10 (midcycle; n ¼ 6), and Day 16 (late stage; n ¼ 5) CL were collected. For Day 4 CL, the ovary was removed by colpotomy from animals under epidural anesthesia (2% [w/v] mepivacaine hydrochloride, 0.01 ml/kg body wt; Upjohn). The CL was then dissected from the ovarian stroma. The Days 10 and 16 CL were removed from the ovary by enucleation. Additionally, to further define the temporal gene expression pattern during luteal regression, PGF 2a (25 mg) was injected intramuscularly into cows on Day 10 of the estrous cycle, and CL (n ¼ 4 per time point) were collected 0.5, 1, 2, 4, 8, and 12 h after treatment.
Transcriptional Profiling
To profile gene expression patterns at the early onset of luteal regression, total RNA was extracted from pooled CL obtained 0.5 h after PGF 2a injection into cows on Day 6 of the estrous cycle. Gene profiling analysis was performed at the Microarray Core Facility, Children's Hospital Boston. Briefly, cDNA was synthesized from RNA and then transcribed into RNA labeled with biotin before processing and hybridization onto the Affymetrix GeneChip U133A probe array. After scanning, hybridization profiles between Day 6 salineinjected control and PGF 2a -treated luteal samples were then analyzed using the Affymetrix Suit software. Genes with expression that exhibited at least a 2-fold difference compared to the controls were then selected for further verification and analysis.
Cell Culture
Corpora lutea (n ¼ 4) were collected from cows on Day 10 of the estrous cycle. LSCs were dissociated as previously described [34] . Briefly, luteal tissues were minced before placement into a spinner flask containing 25 ml of Ham F-12 with 1% bovine serum albumin (BSA) and type I collagenase (2000 U/g tissue; Worthington Biochemical) for 1 h at 378C. During this period, tissues were triturated every 10 min. After 1 h, dissociated cells were centrifuged sequentially at 190 3 g, 110 3 g, and 80 3 g to remove collagenase, connective tissues, and other tissue debris. Cell viability and number were determined by trypan blue exclusion and counting with a hemocytometer, respectively.
Luteal steroidogenic cells were seeded into six-well plates (4 3 10 5 cells/ well) containing 2 ml of Ham F-12 culture medium supplemented with insulin/ selenium/transferrin (5 lg/5 lg/5 ng/ml; Sigma) and gentamicin (30 lg/ml; GIBCO-BRL). After an overnight incubation, unattached cells were removed by rinsing with fresh Ham F-12 medium. LSCs were then treated with 1 lM PGF 2a for 0.5, 2, 12, and 24 h. Cells were enumerated before and after treatment at each time. Cells were then processed for total RNA extraction according to the method described in the next section.
Luteal-derived endothelial cells (generously provided by Dr. Bo Rueda, Massachusetts General Hospital, Boston, MA) were isolated from Day 10 bovine CL as previously described [35] . LDECs (passages 4-9) were seeded into six-well plates (1 3 10 5 cells/well) and cultured in endothelial cell growth medium (EBM-2) containing growth factors and 10% fetal bovine serum (BioWhittaker, Inc.) for 2 days. After starvation with growth factor-free, serumfree EBM-2 medium for 6 h, cells were treated with 1 lM PGF 2a in serum-free EBM-2 medium for 0.5, 2, 12, and 24 h and subsequently processed for total RNA extraction according to the method described in the next section. To study the effect of CYR61 on the endothelin system in the CL, LDECs were treated with 10 or 1000 ng/ml of CYR61 for 1 h. The LDECs from three different passages were used to perform three replicate experiments, and total RNA was then extracted from cells for RT-PCR analysis.
Semiquantitative RT-PCR
Total RNA was isolated from luteal tissue or from cultured luteal steroidogenic and endothelial cells using RNeasy Spin Columns (Qiagen). One microgram of total RNA was reverse transcribed to first-strand cDNA using Supertranscriptase III (Invitrogen). PCR was accomplished using primers for detecting CYR61 (forward, 5
0 ), and endothelin-converting enzyme 1 (ECE1; forward, 5 0 -ACACAACCAAGCCATCATCA-3 0 ; reverse, 5 0 -CAGGGTGTCCTG-GAAGTTGT-3 0 ) with ''hot start'' at 948C for 3 min, followed by 28 cycles of 948C for 30 sec, 548C for 30 sec, and 728C for 30 sec. Bovine glyceraldehyde phosphate dehydrogenase (GAPDH; forward, 5 0 -TGTTCCAG-TATGATTCCACCC-3 0 ; reverse, 5 0 -GTCTTCTGGGTGGCAGTGAT-3 0 ) was run as an internal control. The PCR products were fractionated on 3% agarose gels, and the intensities of PCR bands were determined using the UN-SCAN-IT gel automated digitizing system (Silk Scientific Corporation). The CYR61, EDN1, and ECE1 were expressed as a ratio of their individual intensities to GAPDH.
Western Blot Analysis
Total protein was extracted from luteal tissues and luteal steroidogenic and endothelial cells as previously described [19, 20] , and equal amounts of proteins were subjected to Western blot analysis. Proteins were separated on 4%-12% SDS-PAGE under reducing conditions and then electrophoretically transferred onto nitrocellulose membranes (Invitrogen). Nonspecific binding 262 sites were blocked by incubating the membranes with 5% (w/v) nonfat dry milk in TBST buffer (10 mM Tris-HCl, 150 mM NaCl, and 0.05% [v/v] Triton X-100; pH 8.0). Membranes were then incubated with rabbit anti-human CYR61 antibody (1:250; Abcam). After extensive washes with TBST buffer (five times, 15 min per wash), horseradish peroxidase-conjugated anti-rabbitimmunoglobulin (Ig) G (1:10 000) was applied onto membranes as a secondary antibody. Signals were detected with the SuperSignal West Pico Chemiluminescent Substrate (Pierce) according to the manufacturer's instructions. Human recombinant CYR61 protein expressed from the Baculovirus-sf9 cell system was used as positive control.
Immunofluorescence
Sections (thickness, 6 lm) were prepared from Day 4, Day 10, and Day 16 CL frozen in OCT (Sakura Finetek) using a Cryotome (Shandon). Sections were fixed in cold acetone for 5 min. Nonspecific sites were blocked by 10% (w/v) BSA before incubating the slides with mouse anti-human CYR61 antibody (1:
Expression and Purification of Human Recombinant CYR61
We used human recombinant CYR61 to further investigate the regulatory effect of this protein on endothelial cells. Human CYR61 cDNA (a generous gift from Dr. Lester Lau, University of Illinois at Chicago College of Medicine) was fused with 63HIS Tag at the C-terminus and then inserted into the Baculovirus Transfer Vector pVL1393. The recombinant Baculovirus was generated by cotransfection of the recombinant transfer vector and BaculoGold DNA into sf9 cells according to the manufacturer's instructions (BD Pharminogen). Recombinant CYR61 protein was expressed by monolayer sf9 cells for 4 days after infection. The conditioned medium was then run through an Ni-NTA Agarose column (Qiagen). The purified CYR61 protein was confirmed by SDS-PAGE and Western blot analysis (data not shown). To investigate the regulatory effect of CYR61 on endothelial cells, recombinant CYR61 protein (10 or 1000 ng/ml) was incubated with LDECs for 1 h.
Data Analysis
Densitometric intensities of bands on PCR gels and Western blots were determined using the UN-SCAN-IT gel automated digitizing system. Data were then analyzed by ANOVA followed by Tukey test of pairwise comparisons to determine differences between groups.
RESULTS
Upregulation of CYR61 by PGF 2a at the Onset of Luteal Regression
To characterize gene expression during the early onset of luteal regression, we injected PGF 2a into cows on Day 6 of the estrous cycle. CL were collected 0.5 h later. Gene expression profiling was achieved using Affymetrix GeneChip U133A. Those genes with changes above 2-fold were selected for further verification and characterization. Among the 50 differentially expressed genes, CYR61, a cysteine-rich angiogenic inducer, was increased by 2.4-fold, which was confirmed by RT-PCR (Fig. 1A) . This was a gene of significant interest because of its direct association with angiogenesis. In the Day 10 and Day 16 CL, PGF 2a also significantly stimulated (P , 0.01) CYR61 expression when compared to their respective contemporaneous saline-injected controls (Fig. 1B) .
Transient Stimulation of CYR61 In Vivo Following PGF 2a Administration
To further define the temporal expression of CYR61 during luteal regression, CL were collected 0.5, 1, 2, 4, 8, and 12 h after PGF 2a administration on Day 10 of the estrous cycle. Similar to the gene microarray analysis, CYR61 mRNA was dramatically increased (P , 0.05) relative to untreated controls at 0.5 and 1 h after PGF 2a (Fig. 2) . CYR61 then declined and was significantly decreased (P , 0.05) at 8 and 12 h (Fig. 2) .
Localization of CYR61 in LSCs
To identify the cellular source(s) of CYR61 expression, tissue sections were dually stained with CYR61 antibody and the steroidogenic cell marker cytochrome p450 SCC enzyme, respectively. Dual staining of CYR61 and p450 SCC enzyme was conducted on midcycle, Day 10 CL (Fig. 3, A and B) , a time when progesterone biosynthesis is very high. The colocalization of CYR61 and cytochrome p450 SCC enzyme indicated that LSCs are a source of CYR61 (Fig. 3C) .
Regulation of CYR61 in LSCs But Not in LDECs by PGF 2a In Vitro
To study the regulation of CYR61 expression by PGF 2a in vitro, luteal steroidogenic and endothelial cells were isolated and treated with PGF 2a for 0.5, 2, 12, and 24 h. Although PGF 2a had no effect (P . 0.05) on CYR61 expression in LDECs (Fig. 4, B and C) , it significantly stimulated the CYR61 transcript in LSCs at 0.5 and 2 h posttreatment (Fig. 4, A and  C) . This temporal regulatory effect of PGF 2a on CYR61 in LSCs is similar to its in vivo expression profile during luteal 
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regression, suggesting that the LSCs, rather than endothelial cells, were the primary cell population in the CL contributing to the PGF 2a -induced increase of CYR61 expression.
Differential Expression of CYR61 Transcript and Protein in CL Obtained Over the Estrous Cycle
Over the course of the estrous cycle, the CL undergoes angiogenesis, angiomaintenance, and angioregression. We demonstrated that the CYR61 transcript was highly expressed in the early stage, young, developing Day 4 CL but was dramatically decreased (P , 0.01) in the Day 10 and Day 16 CL (Fig. 5) . Similar to other angiogenic factors (e.g., VEGF and FGF), CYR61 is a secreted protein and associated with the ECM. Using total protein extracts from luteal tissues, Western blot analysis detected CYR61-immunoreactive protein (Fig. 6A) , which showed the highest (P , 0.05) concentration in the day 4 CL, and less in the Day 10 and Day 16 CL (Fig. 6B) .
Reduction of ECE1 Expression by CYR61 in LDECs
Because LDECs were unresponsive to PGF 2a (with respect to CYR61), we investigated whether CYR61 of LSC origin had a possible role in luteal regression by studying its effect on the endothelin system in LDECs. Given the rapid upregulation of CYR61 in vivo, LDECs were treated with 10 or 1000 ng/ml of CYR61 for 1 h. Analysis by RT-PCR demonstrated that neither concentration of CYR61 affected the expression of EDN1 (Fig.  7) . However, the expression of ECE1 was reduced (P , 0.05) by the higher, but not by the lower, concentration of CYR61 (Fig. 7) . 
264
DISCUSSION
Angiogenesis is a hallmark of CL development and function [2] . It is switched on during the folliculoluteal transition and then switched off during angioregression. Although several angiogenic factors, including VEGF [22, 27, 28] , FGF2 in the cow [14, 25] , and PROK1 in the human [26] are expressed by the CL, the interplay between them is not fully understood. In the present study, we identified CYR61, a cysteine-rich angiogenic inducer, in the bovine CL and found that during the early onset of luteal regression in vivo, CYR61 was transiently stimulated by 0.5 and 1 h following administration of PGF 2a , returning to control concentrations at 2 h. Afterward, CYR61 fell below control levels and remained there for the duration of the treatment period. This response to PGF 2a is quicker than that observed with a benign human endometrial cell line, in which CYR61 mRNA was increased at 2 h after treatment and not before [36] . Because multiple PGF 2a pulses are necessary to complete luteolysis in the cow [37] , we propose that CYR61, as an early response gene, may play a role in maintaining blood vessel integrity, which is necessary for the transportation of cell debris during the early onset of luteal regression. This is most likely achieved in cooperation with FGF1 and FGF2. The immediate response of CYR61 at 0.5 h to PGF 2a , followed by its decline at 2 h, precedes expression of both FGF1 and FGF2. Specifically, FGF1 and FGF2 increase later than CYR61 (i.e., between 2 and 12 h before decreasing at 48 h after PGF 2a administration in the cow [38] ). Because CYR61 works synergistically with FGF2 to increase endothelial cell proliferation [39] , the sequential expression of CYR61 [2, 40] .
It is worth noting that single injections of PGF 2a into cows on or before Day 5 of the estrous cycle do not cause luteal regression, whereas single injections administered starting on Day 6 of the estrous cycle do [41, 42] . One explanation for the lack of sensitivity to PGF 2a by bovine CL younger than Day 5 may be a lack of a well-developed vascular system, despite the fact that angiogenesis is at a high rate at this time. This is consistent with the findings of Shirasuna et al. [43] , who reported that the distribution of capillaries and arteriolovenous blood vessels change in cow CL between Day 4 and Day 10. However, this alone may not fully explain the differential sensitivity to PGF 2a between early (younger than Day 5) and midcycle (Days 5-17) bovine CL. This differential sensitivity is not due to a lack of PGF 2a receptors, because high-affinity PGF 2a receptors are expressed by the Day 4 CL [44] . Instead, other researchers suggest that differences in expression of postreceptor signal transduction pathways or regulatory molecules may account for the resistance to PGF 2a by CL younger than Day 5. For example, the mRNA expression of the steroidogenic acute regulatory protein (STAR) is decreased in the midcycle (Day 11) but not in the early (Day 4) bovine CL after PGF 2a treatment in vivo [44] . In contrast, PGF 2a increases progesterone production in vitro by the midcycle (Days 8-12 ) microdialyzed bovine CL or dispersed luteal cells [45, 46] . Furthermore, PGF 2a treatment fails to increase prostaglandin endoperoxide synthase 2 and, subsequently, intraluteal PGF 2a production in the Day 4 bovine CL [44] , but it increases 15-hydroxyprostaglandin dehydrogenase, which breaks down PGF 2a , in the Day 4 ovine CL [47] . In addition, whereas PGF 2a decreases expression of VEGF and FGF2 in the Day 10 midcycle bovine CL, it increases them in the Day 4 CL [43] . Collectively, distinct pathways appear to regulate the responses to PGF 2a by the early (Day 4) and midcycle bovine CL.
We also found that LSCs and LDECs are sources of CYR61, but that only LSCs responded to PGF 2a in vitro by upregulating CYR61 expression. A lack of response by bovine LDECs could be explained by the absence of PGF 2a receptors [48, 49] , although others [50, 51] have reported that these receptors are present. This discrepancy may be due to methodological differences in receptor detection and culture conditions or to the fact that subpopulations of microvascular endothelial cells are resident in the bovine CL [52] . We conclude, based on the present data, that PGF 2a regulated CYR61 in steroidogenic, but not endothelial, cells in the bovine CL.
Given the lack of response by LDECs to PGF 2a , cross-talk between LSCs and LDECs may exist, whereby PGF 2a acts on LSCs to upregulate CYR61, which in turn acts on LDECs. Similar cellular interactions within the bovine CL have been suggested by Townson [53] and Liptak et al. [54] between immune and endothelial cells. To test our hypothesis, we performed a preliminary experiment, which showed that CYR61 decreased expression of ECE1, but not of EDN1, by LDEC. Endothelin 1 is a very potent vasoconstrictive agent. It is synthesized as an inactive, 203-amino-acid preproendothelin. After proteolytic processing of preproendothelin to big endothelin, it is converted to an active, 21-amino-acid peptide by ECE1 [55, 56] . PGF 2a elevates EDN1 expression in vitro and in vivo [57, 58] in the cow. Whereas endothelial cells are the major source of EDN1, both bovine luteal steroidogenic and endothelial cells also synthesize ECE1 [59] . Given our present findings and those published previously, we propose that CYR61 may locally regulate the activity of EDN1 through ECE1. Following PGF 2a , EDN1 secretion from endothelial cells is elevated. At the same time, LSCs increase CYR61, which acts on endothelial cells to reduce ECE1 expression. This results in decreased availability of bioactive EDN1 in the endothelium compartment, which contributes to blood vessel integrity during the early onset of luteal regression and could therefore explain the previously observed transient and acute increase in luteal blood flow in the cow that occurs 0.5-2 h after PGF 2a [60] .
Our data also showed that CYR61/CYR61 was highly expressed in the young, developing Day 4 bovine CL, consistent with its function as an angiogenic inducer. Knockout of the CYR61 gene leads to a defect in vessel bifurcation and, consequently, an undervascularized placenta, causing embryonic death [61] . CYR61 promotes endothelial cell adhesion [62, 63] , stimulates chemotaxis in human microvascular endothelial cells [64] , and is a potent stimulator of angiogenesis in vivo [65] . Another angiogenic regulator, VEGF, is expressed by the bovine CL [28] , and CYR61 is capable of stimulating VEGF expression [66, 67] . VEGF also upregulates CYR61 in human umbilical vein endothelial cells [68] ; therefore, the coincident expression of these two potent angiogenic factors, along with FGF2, may work synergistically to promote the high rate of angiogenesis known to occur during the early formation of the CL [1] . With CYR61 and VEGF being localized to granulosa-derived luteal cells, they may serve as chemoattractants to induce the directed migration of endothelial cell from the theca layer into the previously avascular cavity of the ruptured follicle. This migration through the ECM is accomplished by locally produced MMPs (e.g., in the cow [3, 32, 69] ), which facilitate detachment of endothelial cells from the basement membrane.
Similar to VEGF, an interaction may also exist between CYR61 and FGF2. Even though CYR61 alone does not stimulate endothelial cell proliferation, it augments the mitogenic activity of FGF2 on endothelial cell proliferation. As a heparin-binding protein, CYR61 is capable of displacing FGF2 from the ECM and, consequently, increasing its local bioavailability [39] , resulting in increased proliferation of endothelial cells during the early stage of the estrous cycle.
In summary, we have identified CYR61 as a potential molecular mediator of angiogenesis in the CL. Luteal steroidogenic and endothelial cells are sources of CYR61. Its transient upregulation by PGF 2a in vivo suggests a possible role for CYR61 in endothelial cell survival and maintenance of the vasculature during the early onset of luteolysis. Furthermore, the luteal steroidogenic and endothelial cells may interact such that PGF 2a -stimulated CYR61 from steroidogenic cells decreases ECE1 expression by endothelial cells, which may play a role in the transient increase in blood flow observed during the early onset of luteolysis in cows. The high expression of CYR61 in the developing Day 4 bovine CL affirms its role in the angiogenesis that accompanies luteal formation. Taken together, these results suggest that CYR61 may be a pivotal regulator of the angiogenic switch during the life span of the CL.
